Trump explodes tariff bomb on India: Announces 200% tariff on generic medicines, India will suffer huge losses
Donald Trump Imposed 200% Tariff On Generic Drugs: US President Donald Trump has dropped the tariff bomb on India. In fact, Donald Trump has announced an aggressive tariff policy on foreign generic medicines. Under this scheme, no tariff will be imposed for the initial two years. After this, 100% and then 200% tariff will be imposed on generic medicines. This decision of Trump will have a dire impact on India, which is called the ‘pharmacy of the world’. India exports generic medicines to America on a large scale. After this announcement by Trump, India may suffer severe losses.
US President Donald Trump said in a post that this tariff plan will be implemented in several phases. According to Trump, the purpose of this step is to increase the production of pharmaceutical drugs in America.
Trump said in a post on his social media platform Truth Social that this tariff plan will be implemented in several phases and will start from August 1. Trump wrote on social media – From August 1, 2026, the tariff on all generic medicines coming to America will be zero for 2 years. After this the tariff will be increased to 100% for one year and then to 200% after that. He further said, “This is being done to bring the production of generic medicines back to America. Those companies which will not build plants and equipment within the stipulated time frame, they will be fined.
Let us tell you that the world’s largest pharmaceutical companies had made agreements with the US government last year, under which medicines worth billions of dollars were exempted from tariffs. Trump had signed an executive order in April, under which it was said to impose 100 percent tariff on branded medicines imported into America. This will not apply unless manufacturers accept the government’s drug pricing agreements or promise to manufacture their products within the country.
What will be the impact on Indian pharma sector?
About 40% of generic drugs consumed in the US come from India. The US market is the largest source of revenue for Indian pharma companies (such as Sun Pharma, Dr. Reddy’s, Cipla, Lupine, and Aurobindo Pharma). Indian companies will not face any immediate financial shock due to 0% tariff for two years. Exports from India will continue during this period and companies will have time to make new strategies. After 2 years, when 100% and 200% tariff will be implemented, medicines of Indian companies will become very expensive in the American market. This will put huge pressure on their profit margins.
| Year | month | US million dollars |
| 2025 | april | 41.05 |
| 2025 | May | 46.10 |
| 2025 | june | 50.60 |
| 2025 | july | 49.87 |
| 2025 | august | 44.79 |
| 2025 | september | 45.79 |
| 2025 | october | 40.79 |
| 2025 | november | 41.23 |
| 2025 | December | 53.09 |
| 2026 | January | 51.95 |
| 2026 | February | 47.42 |
Highest export to America
According to IEBF data, India exports pharmaceutical products to North America, Africa, EU, ASEAN, Latin America and the Caribbean (LAC), Middle East, Asia, CIS and other regions of Europe. During FY 2025, India has exported to more than 200 countries across the world. About 50% of India’s exports go to markets with stringent regulations like North America and Europe. The top five export countries for the Indian pharma industry in FY 2025 were USA, UK, Brazil, France and South Africa. The top importing countries from India during FY 2025 were USA, UK and Brazil, whose share was 34.61%, 3.01% and 2.56% respectively. The top importing countries from India during FY 2026 (April-July) were USA, UK and South Africa, whose share was 34.06%, 2.91% and 2.40% respectively.
PM Modi gifts Melody Toffee to Meloni, Italy’s Prime Minister jumps with joy
Follow the LALLURAM.COM MP channel on WhatsApp
Comments are closed.